Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex’ Oral-lyn matches fast-acting insulin
This is the first report in which patients with type-1 diabetes, using glargine insulin (Sanofi-Aventis’ Lantus) as their baseline therapy, have been maintained with optimal control using a
This is the first report in which patients with type-1 diabetes, using glargine insulin (Sanofi-Aventis’ Lantus) as their baseline therapy, have been maintained with optimal control using a
The phase I clinical trial is the first of a planned series of studies examining the safety and pharmacokinetics of PBT2 in normal human volunteers. PBT2 is the
Under the agreement, Benchmark will manufacture Probactrix for BioBalance’s proposed clinical trials in the US once BioBalance receives FDA clearance to proceed with those trials. The product will
The company’s announcement is based on the outcome of a meeting with the FDA on March 11. La Jolla plans to continue the ongoing clinical benefit trial and
The class action lawsuit was filed against American Pharmaceutical Partners, certain of its officers and American BioScience, the company’s strategic partner for Abraxane, while a related derivative lawsuit
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) generally used for the treatment of inflammation and pain and available in the US only in oral form. Under the terms
The sufentanil patch, which is in early-stage clinical development, employs Durect’s proprietary Transdur drug-adhesive matrix formulation and is intended to provide relief of moderate-to-severe chronic pain for up
The results of the three-month pilot confirm that radio-frequency identification (RFID) tags and printed barcodes can be mass-deployed and that pharmacists are keen to gain the advantages of
These findings, published in The Journal of Clinical Endocrinology & Metabolism, demonstrate the important role growth hormone (GH) treatment may play in reducing serious metabolic conditions, such as
Ecole Polytechnique Federale de Lausanne (EPFL) scientists used RNA interference in transgenic mice to silence a mutated gene that causes inherited cases of amytrophic lateral sclerosis (ALS, or